QuantiFERON-Monitor: A novel biomarker of immune function following lung transplantatio

Not Applicable

Completed

• Conditions: ung Transplantation; Chronic Allograft Dysfunction; Cytomegalovirus; Lung Transplantation; Respiratory - Other respiratory disorders / diseases; Infection - Other infectious diseases; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12615000747527
• Lead Sponsor: The Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-07-20
• Study Completion: 2018-07-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Adult (greater than or equal to 18 years)
Single or Bilateral Lung Transplant or Heart-Lung Transplant Recipient
Provided informed Consent

Exclusion Criteria

Repeat transplant recipients
Unable to peform their 12 month follow-up at our site.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of immune monitoring with the QFN-Monitor assay in patients undergoing lung transplantation.<br>The QFN-Monitor test results will be observationally compared to patients clinical immune state, including routine IgG levels.<br>This outcome is to evaluate if a relationship is present between the clinical immune status of a lung transplant receipient and the QFN-Monitor results.[Assessment of immune state, including the QFM and QFN-CMV tests, will occur pre-transplant, and at 5 time points in the first 12 months post transplant. These being 2 and 6 weeks and 3, 6 , 12 months post transplant.]